Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma

Japanese Journal of Radiology

Volumn 30, Issue 9, 2012, Pages 735-742

  Oguro, Sota ^a   Hashimoto, Subaru ^a   Tanaka, Tomoki ^a   Inoue, Masanori ^a   Nakatsuka, Seishi ^a   Kuribayashi, Sachio ^a   Asakura, Keiko ^a   Kawachi, Shigeyuki ^a   Tanabe, Minoru ^a   Kitagawa, Yuko ^a   Ebinuma, Hirotoshi ^a   Saito, Hidetsugu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Hepatocellular carcinoma; Miriplatin; Multivariate logistic regression; Transcatheter arterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; IODINATED POPPYSEED OIL; MIRIPLATIN; ANTINEOPLASTIC AGENT; ETHIODIZED OIL; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CREATININE BLOOD LEVEL; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUSPENSION; THERAPY EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; VOMITING; CATHETERIZATION; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SUSPENSIONS; TREATMENT OUTCOME;

EID: 84877059903     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-012-0116-1     Document Type: Article

References (29)

1. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71. (Pubitemid 34454013)
2. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. (Pubitemid 34607087)
3. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer. 2000;88:1574-81. (Pubitemid 30183142)
4. Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23:564-8. (Pubitemid 32429101)
5. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol. 2001;12:847-54. (Pubitemid 32642435)
6. Kawai S, Tani M, Okamura J, Ogawa M, Ohashi Y, Monden M, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol. 1997;24:S6-38-45.
7. Achenbach T, Seifert JK, Pitton MB, Schunk K, Junginger T. Chemoembolization for primary liver cancer. Eur J Surg Oncol. 2002;28:37-41. (Pubitemid 41122780)
8. Ikeda M, Maeda S, Shibata J, Muta R, Ashihara H, Tanaka M, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology. 2004;66:24-31. (Pubitemid 38410676)
9. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res. 2008;38:474-83. (Pubitemid 351593948)
10. Moriguchi M, Takayama T, Nakamura M, Aramaki O, Higaki T, Nakayama H, et al. Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol Res. 2010;40:369-75.
11. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs. 2011;22:277-82.
12. Kitamura A, Shimakura J, Yabuki M, Asano H, Fukuoka T, Nakano M, et al. Pharmacokinetics of miriplatin in experimental dog models of hepatic or renal impairment. Eur J Drug Metab Pharmacokinet. 2011;36:213-22.
13. Watanabe S, Nitta N, Ohta S, Sonoda A, Otani H, Tomozawa Y, et al. Comparison of the anti-tumor effects of two platinum agents (miriplatin and fine-powder cisplatin). Cardiovasc Intervent Radiol. 2012;35:399-405.
14. Okabe K, Beppu T, Haraoka K, Oh-Uchida Y, Yamamura S, Tomiyasu S, et al. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res. 2011;31:2983-8.
15. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2009;100:189-94.
16. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-83.
17. Morimoto K, Sakaguchi H, Tanaka T, Yamamoto K, Anai H, Hayashi T, et al. Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer. Cardiovasc Intervent Radiol. 2008;31:981-5.
18. Kim HC, Chung JW, Jae HJ, Yoon JH, Lee JH, Kim YJ, et al. Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology. 2010;257:278-87.
19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
20. Yamanaka K, Hatano E, Narita M, Taura K, Yasuchika K, Nitta T, et al. Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res. 2011;41:303-9.
21. Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, et al. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011;80:188-94.
22. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. (Pubitemid 44900485)
23. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10:425-34.
24. Sahara S, Kawai N, Sato M, Minamiguchi H, Nakai M, Takasaka I, et al. Prospective comparison of transcatheter arterial chemoembolization with lipiodol-epirubicin and lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol. 2010;28:362-8.
25. Miyayama S, Yamashiro M, Shibata Y, Hashimoto M, Yoshida M, Tsuji K, et al. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. 2012;30:263-70.
26. Malinge JM, Giraud-Panis MJ, Leng M. Interstrand cross-links of cisplatin induce striking distortions in DNA. J Inorg Biochem. 1999;77:23-9. (Pubitemid 30089077)
27. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, et al. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis. Aliment Pharmacol Ther. 2009;29:1291-8.
28. Yoon HJ, Kim JH, Kim KA, Lee IS, Ko GY, Song HY, et al. Transcatheter arterial chemo-lipiodol infusion for unresectable hepatocellular carcinoma in 96 high-risk patients. Clin Radiol. 2010;65:271-7.
29. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagege H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129-34. (Pubitemid 28307992)